Literature DB >> 15614313

Early Diagnosis and Treatment of Dementia Presenting as Transient Global Amnesia in a 76-Year-Old Man.

Erno S Daniel1.   

Abstract

This article reports the case of a high-functioning patient who had an "event" diagnosed as probable transient global amnesia (TGA) 1 year before being diagnosed with evolving cognitive impairment. Formal psychometric testing was necessary to make this diagnosis owing to the insensitivity of simple tests in this high-functioning individual. Neuropsychological evaluation showed impairment of short-term verbal memory, compounded by observed fluctuations in attention. In light of its reported benefits for cognitive function and attention, galantamine was administered starting at 4 mg b.i.d., then increasing to 8 mg b.i.d. and finally to 12 mg b.i.d. During galantamine dose escalation, the patient experienced transient vomiting on the first day of taking 12 mg b.i.d. With reassurance, he returned to the same dose and tolerated it during long-term treatment without problems. His cognitive function has remained at an improved level for 18 months on galantamine administration.

Entities:  

Year:  2004        PMID: 15614313      PMCID: PMC535652          DOI: 10.4088/pcc.v06n0606

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  15 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Contrast study on cognitive function with MRI and positron emission tomography imaging in transient global amnesia.

Authors:  Jianjun Jia; Luning Wang; Ling Yin; Hongchuan Tang
Journal:  Chin Med J (Engl)       Date:  2002-09       Impact factor: 2.628

3.  Syndromes of transient amnesia: towards a classification. A study of 153 cases.

Authors:  J R Hodges; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

Review 4.  Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.

Authors:  A Maelicke; M Samochocki; R Jostock; A Fehrenbacher; J Ludwig; E X Albuquerque; M Zerlin
Journal:  Biol Psychiatry       Date:  2001-02-01       Impact factor: 13.382

5.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.

Authors:  G K Wilcock; S Lilienfeld; E Gaens
Journal:  BMJ       Date:  2000-12-09

6.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

7.  Transient global amnesia: a clinical and sonographic study.

Authors:  N Maalikjy Akkawi; C Agosti; G P Anzola; B Borroni; M Magoni; A Pezzini; L Rozzini; L A Vignolo; A Padovani
Journal:  Eur Neurol       Date:  2003       Impact factor: 1.710

8.  Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Authors:  K Rockwood; J Mintzer; L Truyen; T Wessel; D Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

9.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years.

Authors:  D Galasko; S D Edland; J C Morris; C Clark; R Mohs; E Koss
Journal:  Neurology       Date:  1995-08       Impact factor: 9.910

10.  Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01).

Authors:  Paulo Caramelli; Márcia L F Chaves; Eliasz Engelhardt; João Carlos B Machado; Rodrigo R Schultz; Francisco A C Vale; Helenice Charchat-Fichman
Journal:  Arq Neuropsiquiatr       Date:  2004-07-20       Impact factor: 1.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.